NRx Pharmaceuticals plans to seek FDA approval for NRX-100, a preservative-free ketamine therapy for severe depression with suicidal ideation, following supportive Type C meeting feedback.
Written By: Anand Sathappan, BPharm
Reviewed By: Pharmacally Editorial Team
NRx Pharmaceuticals announced that the U.S. Food and Drug Administration has signaled willingness to review the company’s New Drug Application (NDA) for NRX-100, a preservative-free intravenous ketamine formulation, for the treatment of severe depression in patients who may have suicidal ideation. The feedback follows an in-person Type C guidance meeting with leadership from the FDA’s Division of Psychiatry Products, Office of Neuroscience, and Center for Drug Evaluation and Research.
According to meeting minutes confirmed by the agency, the FDA is open to reviewing the application based on substantial evidence of effectiveness derived from existing adequate and well-controlled clinical trials, meaning additional clinical trials will not be required. NRx will submit patient-level data from previously completed studies as part of the NDA package.
In the studies reviewed with regulators, ketamine demonstrated significant superiority to placebo and active placebo, along with non-inferiority compared with electroconvulsive therapy (ECT). The trials also showed statistically significant reductions in suicidal ideation.
While ECT remains the only currently approved treatment specifically used in severe suicidal depression, it has been associated with about 30% incidence of memory loss, an effect not observed with ketamine in the analyzed studies.
The FDA also indicated it would consider real-world evidence as confirmatory support for the application. Preliminary analyses of real-world data suggest intravenous ketamine may effectively reduce both depressive symptoms and suicidal thoughts.
Based on the agency’s guidance, NRx plans to pursue a broader indication for severe depression in patients who may experience suicidal ideation, rather than its earlier plan focused only on patients actively experiencing suicidal thoughts. According to the U.S. Centers for Disease Control and Prevention, more than 16 million Americans experience depression each year, and approximately 3.6 million contemplate suicide annually.
Regulators further confirmed that no additional nonclinical studies or bridging studies would be required to support the company’s preservative-free ketamine formulation. NRx expects the formulation to offer at least three years of room-temperature shelf stability, which may support broader clinical use.
“We deeply appreciate the FDA’s supportive meeting with us at the leadership level and guiding us to pursue a New Drug Application for NRX-100 for the benefit of the millions of Americans with severe depression,” said Dr. Jonathan Javitt, founder, chairman, and CEO of NRx Pharmaceuticals, adding that the company hopes the therapy could help address suicide, which remains a leading cause of death among Americans under 35.
In parallel, NRx is pursuing an Abbreviated New Drug Application (ANDA) for preservative-free ketamine for its currently approved use in anesthesia. The FDA accepted that application in September 2025 and assigned a Summer 2026 decision date.
Reference
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting, 16 March 2026, https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-confirms-path-new-drug
About the Writer
Anand Sathappan is a pharmacy graduate with interests in pharmaceutical sciences, pharmacology, and medical writing. He also holds certification in medical coding and has familiarity with pharmacology and healthcare documentation. He has completed the Medical Writing Skills for Beginners program offered by the International Medical Writers Association (IMWA). His work focuses on exploring developments in pharmaceuticals and presenting scientific information in a clear and structured manner.